Skip to main content
Observe Medical logo

Observe Medical — Investor Relations & Filings

Ticker · OBSRV ISIN · NO0010865009 LEI · 9845005F38B74FFJ1B65 Euronext Expand Manufacturing
Open in API
Filings indexed 643 across all filing types
Latest filing 2023-11-17 Declaration of Voting R…
Country NO Norway
Listing Euronext Expand OBSRV

About Observe Medical

https://observemedical.com/

Observe Medical is a medical technology company that develops, markets, and sells innovative medtech products for the global market. The company is committed to improving patient welfare and outcomes, increasing clinical data accuracy, and promoting positive health economics. It is building a scalable medtech platform that combines a portfolio of proprietary products with strategic partnerships, leveraging its manufacturing, development, regulatory, and commercial capabilities to bring new technologies to market.

Recent filings

Filing Released Lang Actions
Observe Medical ASA: Correction of attachments to notice of extraordinary general meeting in connection with the proposed rights issue
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text provided is structured as an appendix ('Vedlegg 4 / Appendix 4') containing a table that lists shareholders, their nominal values, and total set-off amounts including interest. This format strongly suggests a disclosure related to a specific financial transaction, capital structure change, or a formal notice regarding shareholder positions or debt settlements. Given the context of financial reporting categories, this data most closely aligns with information regarding capital structure or significant shareholdings/transactions, but it is presented as an attachment or supplementary data rather than a full report. If this were part of a larger filing, it would support categories like Capital/Financing Update (CAP) or Major Shareholding Notification (MRQ). However, since the text itself is a detailed table of specific financial/shareholder data without narrative context or a clear regulatory filing header (like 10-K or ER), and considering the available options, it resembles supplementary financial data or a specific disclosure. It is not an AGM presentation, Audit Report, Management Change, Call Transcript, Delisting, Director Dealing, Earnings Release, ESG report, Governance report, Interest Rate Update, Interim Report, Investor Presentation, Legal Report, M&A activity, Dividend Notice, Proxy Statement, Remuneration Report, or Transaction in Own Shares. It is too specific for a general Regulatory Filing (RNS) and too detailed for a simple Fund Factsheet (FS). It is most likely supplementary data related to a capital event or a specific disclosure required in a larger filing. Given the structure showing nominal values and set-off amounts, it is highly specific financial data. If this were an Excel file, it would be XLSX. Since it is presented as a table within a document, and it details specific financial positions/values, it fits best as supplementary data, though it lacks the typical narrative of an 'Investor Presentation' (IP) or 'Management Report' (MDA). Revisiting the definitions, this looks like a schedule detailing debt holders or specific capital commitments/settlements. Without more context, the closest fit for detailed, structured financial data that isn't a full report is often categorized under supplementary data or a specific financial disclosure. Given the options, and recognizing this is highly specific financial schedule data, I will classify it as Financial Supplement Data (XLSX) if we assume this table represents the content typically found in such a supplement, or potentially a specific disclosure related to capital (CAP). Since it is presented as a table of figures rather than a narrative announcement, and given the high specificity of the data (nominal value vs. set-off amount), it strongly suggests detailed financial schedules. However, the code XLSX is defined as 'Supplementary financial data provided in a detailed Excel spreadsheet format.' Since this is text, not an actual XLSX file, the RPA (Report Publication Announcement) rule might apply if this text is just an excerpt announcing a filing. But the text *is* the data. Given the highly structured, tabular nature detailing specific financial amounts per shareholder, it represents detailed financial data. If this were a standalone document, it would be a schedule. In the absence of a 'Schedule' code, and noting it is not a primary report, I lean towards the most detailed financial data category available that isn't a full report. Since it's not a standard report (10-K, IR), and it's not an announcement of a report (RPA), I will classify it based on the content type: detailed financial figures. This is a very specific disclosure, likely related to debt restructuring or capital structure, making CAP a possibility, but the format is pure data. I will default to the most general specific data category that isn't a full report, which is often where detailed schedules land if they aren't ESG or NAV. Given the lack of clear regulatory headers, and the content being a detailed schedule of financial positions, I will select RNS as the fallback for a specific, non-standard disclosure, or CAP if it relates to financing. The data strongly implies a capital/financing context (set-off amounts, nominal values). I will choose CAP as the most contextually relevant specific category, assuming this schedule details obligations or capital structure elements. Upon final review, this table is a schedule of creditors/shareholders with specific amounts. This is highly specific financial detail, often found in financing documents or detailed schedules accompanying an Annual Report or Interim Report. Since it is not the report itself, and it details financial positions, CAP (Capital/Financing Update) is the most appropriate fit among the specific codes, as it details specific financial obligations/holdings. Confidence is moderate due to the document being in Norwegian/English mix and lacking standard headers.
2023-11-17 English
Observe Medical ASA: Correction of attachments to notice of extraordinary general meeting in connection with the proposed rights issue
AGM Information Classification · 98% confidence The document is an official 'Redegjørelse' (Statement/Report) prepared by an independent auditor (Ernst & Young AS) for the General Meeting of Observe Medical ASA. The purpose is explicitly stated: to provide an independent expert statement regarding a capital increase settled by set-off of debt, as required by Norwegian public limited liability companies act (§ 10-2, cf. § 2-6). This document details the valuation and confirmation that the debt being offset corresponds to the value of the shares issued. This structure—an independent expert report concerning a specific corporate action (capital change/financing) presented to shareholders/the general meeting—fits best under the 'Audit Report / Information' (AR) category, as it is a formal, audited statement on a financial/legal transaction, distinct from a full annual report (10-K) or a simple dividend notice. It is not a general AGM presentation (AGM-R) but a specific legal/audit requirement related to a capital action (CAP), but the core function is the independent audit/statement, making AR the most precise fit among the provided options for a formal, audited statement on a specific financial transaction.
2023-11-17 English
Observe Medical ASA: Correction of attachments to notice of extraordinary general meeting in connection with the proposed rights issue
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (3540 characters) from Observe Medical ASA correcting attachments to a previously announced notice of an extraordinary general meeting (EGM) related to a proposed rights issue. It explicitly states that new versions of Appendix 3 (independent expert report) and Appendix 4 (set-off amounts) are attached to *this* stock exchange announcement and made available on the website. This fits the definition of announcing the publication or correction of related documents rather than being the full report itself. Since it is a formal stock exchange announcement correcting materials for a shareholder meeting (EGM), it is best classified as a general Regulatory Filing (RNS) or potentially related to Capital/Financing (CAP) due to the rights issue context. However, the primary action is the announcement/correction of attached documents, making RPA or RNS the most appropriate fit based on the 'MENU VS MEAL' rule. Given the context is a correction to an EGM notice, RNS (General regulatory announcement/fallback) is a strong candidate, but RPA (Report Publication Announcement) also fits the structure of announcing attached/corrected materials. Since the core event is the correction of materials related to a capital event (rights issue), and it is a formal stock exchange announcement, RNS is chosen as the most encompassing regulatory fallback for this type of correction notice.
2023-11-17 English
Observe Medical ASA: Correction of attachments to notice of extraordinary general meeting in connection with the proposed rights issue
Capital/Financing Update Classification · 90% confidence The document is a correction notice regarding attachments to a notice of an extraordinary general meeting (EGM) concerning a proposed rights issue. It specifically mentions correcting appendices (Appendix 3 and Appendix 4) related to debt conversion and interest calculations for the rights issue. Since the core subject is the correction of materials related to a shareholder meeting (EGM) and associated capital changes (rights issue), it relates closely to corporate governance and capital structure. However, the document itself is a short announcement correcting prior materials, not the full EGM notice or the final voting results. The closest fit among the provided codes is 'CAP' (Capital/Financing Update) due to the focus on the rights issue and debt conversion, or potentially 'RPA' (Report Publication Announcement) as it announces corrected attachments. Given the substance is a correction directly tied to a financing event (rights issue), 'CAP' is more specific than the general announcement category 'RPA'. The document is short and announces corrections to supporting documents for a capital event.
2023-11-17 English
Observe Medical have signed LOI with Vingmed for Nordic distribution of UnoMeter portfolio
Regulatory Filings Classification · 95% confidence The document announces the signing of a Letter of Intent (LOI) for a forthcoming exclusive Nordic distribution agreement between Observe Medical and Vingmed regarding the UnoMeter portfolio. This is a specific corporate event announcement concerning a strategic partnership/distribution deal, which falls under the scope of Merger & Acquisition (M&A) Activity or a general corporate update. Since the definitions do not explicitly cover 'Distribution Agreement LOI', I must evaluate the closest fit. 'M&A Activity (TAR)' covers merger proposals or takeover bids. While this is a distribution agreement, it is a significant strategic transaction that affects future operations and revenue streams, often grouped with M&A-related news in financial databases. Given the options, 'TAR' (M&A Activity) is the most appropriate category for a major strategic partnership announcement, although 'RNS' (Regulatory Filings/General Announcement) is a possibility if TAR is deemed too specific. However, the nature of the announcement (a major commercial agreement) leans towards TAR over a generic RNS filing, especially since it is not a standard regulatory report like 10-K or ER. I will classify it as TAR based on the strategic nature of the transaction.
2023-11-13 English
Observe Medical have signed LOI with Vingmed for Nordic distribution of UnoMeter portfolio
Regulatory Filings Classification · 100% confidence The document announces the signing of a Letter of Intent (LOI) for a forthcoming exclusive Nordic distribution agreement between Observe Medical and Vingmed. This is a specific corporate event announcement concerning a strategic partnership/distribution deal, which falls under the scope of M&A Activity (TAR) if it were a definitive agreement, but since it is an LOI and relates to business operations and future agreements, it is best classified as a general corporate announcement. Given the options, this type of announcement—a significant business development that is not a standard financial report (10-K, IR, ER) or a management/board change—is often categorized under general regulatory filings or specific transaction types. Since it is a major business development announcement (distribution agreement LOI), and there isn't a specific 'Business Development' code, it most closely aligns with M&A Activity (TAR) as it relates to future commercial structure, or potentially Regulatory Filings (RNS) as a catch-all. However, since it is a specific announcement about a commercial agreement, and not a formal filing like a 10-K or a dividend notice, and it is not a management change (MANG) or director dealing (DIRS), the most appropriate category for a significant, non-financial report corporate action announcement is often RNS (Regulatory Filings) if TAR is reserved strictly for takeovers/mergers. Given the context of corporate actions, and the lack of a specific 'Partnership Announcement' code, RNS is the safest fallback for a material, non-standard announcement. Upon review, TAR (M&A Activity) is usually for takeovers/mergers. This is a distribution agreement. Therefore, RNS (Regulatory Filings) is the most suitable general category for this material, non-standard announcement.
2023-11-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.